Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield - Carrier Screening Prior A…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - NebraskaPolicy N/A

    Reproductive Testing: Carrier Screening (Requires Preauthorization)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nebraska policy alerts

    Know when Blue Cross Blue Shield - Nebraska releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and authorization criteria for carrier screening tests used before or during pregnancy to determine parental carrier status for single-gene recessive and X-linked disorders; affects members seeking preconception or prenatal carrier screening and providers ordering these tests.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyReproductive Testing: Carrier Screening (Requires Preauthorization)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewNov 1, 2026
    Next Review DateAug 11, 2026
    Key ActionObtain prior authorization and submit required clinical documentation (history, office notes, genetic counseling report, and panel gene lists) when requesting carrier screening tests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >=9 / >=15Panel gene counts
    CFTR & SMN1Required genes for medical necessity
    CF & SMAACOG recommended
    145 genesExample panel size
    V.31Policy version

    Coverage and Medical Necessity Criteria

    inv-01: Expanded Carrier Screening Panels - Medically Necessary

    Expanded carrier screening panels may be considered medically necessary when ALL of the following are met

    Expanded panel medical necessity

    • Panel composition: The panel includes CFTR and SMN1

    inv-02: Expanded Carrier Screening Panels - Investigational

    Expanded carrier screening panels are considered investigational when the following applies

    Expanded panel investigational: Indication is any other than preconception or pregnancy with panel including CFTR and SMN1

    Investigational for all other indications

    inv-03: Basic Carrier Screening Panels - Medically Necessary

    Basic carrier screening panels may be considered medically necessary when ALL of the following are met

    Basic panel medical necessity: A. The member is considering pregnancy or is currently pregnant

    AND B. The panel includes CFTR and SMN1; basic panels limited to CFTR, SMN1/2, FMR1, HBB/HBA1/HBA2 and not more than 14 genes

    inv-04: Basic Carrier Screening Panels - Investigational

    Basic carrier screening panels are considered investigational when the following applies

    Basic panel investigational: Indication is any other than preconception or pregnancy

    Investigational for all other indications

    inv-05: CFTR Carrier Screening - Criteria

    CFTR carrier screening acceptable indications

    CFTR targeted variant (familial): A. Member and/or reproductive partner is considering pregnancy or is currently pregnant; AND B. Member has a close relative with a known pathogenic or likely pathogenic CFTR variant

    Targeted mutation analysis for known familial mutation is medically necessary

    CFTR sequencing/deletion: A. Member and/or reproductive partner is considering pregnancy or is currently pregnant OR B. Member's reproductive partner is a known carrier for cystic fibrosis

    Sequencing/deletion/duplication or mutation panel using at minimum the ACMG-23 variant panel is medically necessary in these situations

    CFTR intron 9 polyT/TG analysis: A. Member and/or reproductive partner is considering pregnancy or is currently pregnant; AND B. Member is known to have an R117H variant in CFTR

    Intron 9 polyT and TG analysis medically necessary when R117H present

    inv-06: Spinal Muscular Atrophy Carrier Screening - Coverage Note

    SMA coverage note: CPT 81329 (SMN1) is a covered benefit and does not require preauthorization or medical review per policy note

    inv-07: SMN1 Targeted Variant Analysis

    Considered medically necessary when ALL of the following are met

    SMN1 targeted variant analysis: A. The member and/or the member’s reproductive partner is considering pregnancy or is currently pregnant; AND B. The member has a close relative with a known pathogenic or likely pathogenic variant in SMN1.

    If criteria not met, testing considered investigational.

    inv-08: SMN1 Sequencing/Deletion-Duplication Analysis

    Considered medically necessary when ANY of the following are met

    SMN1 sequencing/deletion-duplication and SMN2 analysis: A. The member and/or member’s reproductive partner is considering pregnancy or is currently pregnant; OR B. The member’s reproductive partner is a known carrier for spinal muscular atrophy.

    All other indications are investigational.

    inv-09: Fragile X (FMR1) Carrier Screening

    Considered medically necessary when ANY of the following are met (AND where noted, additional requirements apply)

    FMR1 CGG repeat analysis: A. Member has premature ovarian insufficiency or elevated FSH before age 40; OR B. Member is considering pregnancy or is currently pregnant AND the member has one of: (a) close relative with fragile X syndrome (>200 CGG repeats), (b) close relative who is a known carrier (55-200 repeats), (c) close relative with unexplained intellectual disability/developmental delay/autism spectrum disorder, or (d) close relative diagnosed with premature ovarian insufficiency or elevated FSH before age 40.

    All other indications are investigational.

    inv-10: Hemoglobinopathy Targeted Variant Analysis

    Considered medically necessary when ALL of the following are met

    HBA1/HBA2/HBB targeted variant analysis: A. The member or reproductive partner is considering pregnancy or is currently pregnant; AND B. The member has a close relative with a known pathogenic or likely pathogenic variant in HBA1, HBA2, or HBB.

    If reproductive partner is known carrier, sequencing/deletion-duplication testing for member is likely more appropriate.

    inv-11: Hemoglobinopathy Sequencing/Deletion-Duplication Analysis

    Considered medically necessary when the following is met

    HBA1/HBA2/HBB sequencing/deletion-duplication: The member or the member’s reproductive partner is considering pregnancy or is currently pregnant.

    All other indications, including fetal hemoglobin testing via circulating fetal DNA, are investigational.

    inv-12: Ashkenazi Jewish Carrier Panel

    Considered medically necessary when ALL of the following are met

    Ashkenazi Jewish carrier panel: A. Member or reproductive partner is considering pregnancy or is currently pregnant; AND B. Member is of Ashkenazi Jewish ancestry; AND C. Panel includes at minimum Tay-Sachs (HEXA), Canavan (ASPA), Cystic fibrosis (CFTR), and Familial dysautonomia (ELP1).

    If only one partner is Ashkenazi, testing that partner is medically necessary first; partner tested only if result is positive.

    inv-13: Duchenne and Becker Muscular Dystrophy Carrier Screening

    Considered medically necessary when ALL of the following are met

    DMD targeted variant analysis: A. Member is considering pregnancy or is currently pregnant; AND B. Member has a close relative with a known pathogenic or likely pathogenic variant in DMD.

    Other indications investigational.

    DMD sequencing/deletion-duplication: A. Member is considering pregnancy or is currently pregnant; AND B. Member has a first- or second-degree relative diagnosed with Duchenne or Becker muscular dystrophy.

    Other indications investigational.

    inv-14: Medical necessity criteria

    Covered when consistent with professional guidance and medical records support:

    ACOG Fragile X indication: Fragile X premutation carrier testing is offered when a woman has personal or family history of ovarian failure or elevated FSH before age 40 without a known cause.

    ACOG Practice Bulletin No. 605

    Hemoglobinopathy testing in pregnancy: Universal hemoglobinopathy testing is recommended for individuals considering pregnancy or currently pregnant (at initial prenatal visit); testing may be hemoglobin electrophoresis or molecular expanded carrier screening.

    ACOG Practice Advisory 2022

    Ashkenazi Jewish panel indication: Offer Ashkenazi Jewish carrier panel testing (including CF, Canavan, familial dysautonomia, Tay-Sachs) to individuals of Ashkenazi Jewish descent who are pregnant or considering pregnancy; if only one partner is Ashkenazi Jewish, test that partner first and test partner if carrier identified.

    ACOG Practice Bulletin No. 691

    inv-15: General coverage criteria

    Covered when testing meets panel definitions and preauthorization is obtained

    Panel and authorization requirements: Test must use an approved genomic sequence analysis panel meeting the minimum gene counts specified (eg, Ashkenazi panel >=9 genes; severe inherited conditions panel >=15 genes) and preauthorization must be obtained using the listed CPT/HCPCS codes.see thresholds

    Clinical indication details are in other sections of the policy not included in these chunks

    Expanded and basic carrier screening panels are considered investigational when ordered for indications other than members who are considering pregnancy or are currently pregnant. For both panel types the policy requires that the panel include CFTR and SMN1 to meet medical necessity in the preconception or prenatal context; panels that do not meet these composition and indication requirements are investigational and may be denied.

    Fetal hemoglobin testing performed via circulating fetal DNA is explicitly listed as investigational and excluded from coverage under hemoglobinopathy testing. Hemoglobinopathy sequencing/deletion-duplication testing is medically necessary only when the member or reproductive partner is considering pregnancy or is currently pregnant; other indications, including fetal hemoglobin analysis by circulating fetal DNA, are investigational.

    Fragile X (FMR1) CGG repeat analysis is covered only when the specified criteria are met (for example, women with premature ovarian insufficiency or those who are considering pregnancy/currently pregnant and have relevant close-family findings). Fragile X repeat analysis billed for indications outside the listed criteria is considered investigational and excluded from coverage.

    The policy does not provide a broad explicit exclusion list in the excerpted sections; rather it provides targeted recommendations for ancestry-based panels (for example, Ashkenazi Jewish panel testing) and specifies that such panels are medically necessary only in the prenatal or preconception setting for individuals meeting ancestry and panel composition criteria.

    Unlisted molecular pathology procedures may be reported using CPT 81479; however, coverage determination for unlisted procedures requires review per policy. Providers should submit documentation supporting the test methodology and gene content when requesting authorization for an unlisted molecular pathology code.

    Use of expanded or basic carrier screening panels for indications outside of the preconception or prenatal contexts is considered investigational (not medically necessary). The policy requires that panels intended for coverage in the reproductive context include CFTR and SMN1; panels ordered for other clinical reasons do not meet medical necessity under this policy.

    Multiple disease-specific analyses and expanded panels are explicitly designated investigational when used for indications that do not meet the stated medically necessary criteria (for example, testing when the member is not pregnant/not considering pregnancy, or when qualifying family history or partner-carrier status is absent). The policy lists specific criteria per condition (SMN1, FMR1, hemoglobinopathies, DMD, Ashkenazi panels) and labels other indications outside those criteria as investigational.

    Within the excerpt provided there are no additional explicit statements of 'not medically necessary' conditions attached to the individual CPT/HCPCS codes listed; the policy instead ties medical necessity to the clinical indication and panel definitions rather than assigning code-level noncoverage in this section.

    CPT / HCPCS / Molecular Codes

    Example CPT/HCPCS codes referenced in tablesmixed
    81220CFTR cystic fibrosis gene analysis (carrier testing)
    81221CFTR targeted variant - single test (example referenced)
    81222CFTR sequencing (example referenced)
    81223CFTR deletion/duplication analysis (example referenced)
    81224CFTR intron 9 polyT and TG analysis
    81243FMR1 CGG repeat analysis (Fragile X)
    81244Additional FMR1 testing (example referenced)
    81257Alpha/beta globin targeted variant analysis example
    81258HBA/HBB targeted variant analysis (example referenced)
    81259Alpha-globin sequencing/deletion/duplication (example referenced)
    1–10 of 29
    1/3
    Not requiring preauthorization (specified)CPTCovered
    81329SMN1 (survival of motor neuron 1) Spinal muscular atrophy gene analysis dosage/deletion analysis including SMN2
    Fragile X carrier testingCPT
    81243FMR1 (Fragile X) CGG-trinucleotide repeat analysis
    Expanded carrier screening panelsCPT
    81443Expanded carrier screening panel (example panel code referenced in policy notes)
    Covered CPT-PLA / Proprietary molecular panel codesCPTCovered
    0218UNEURO MUSCULAR DYSTROPHY DMD SEQ ALYS BLD/SALIVA
    0236USMN1&SMN2 FUL GEN ALYS CHNG DUPL&DELET&INSJ
    0400UOB XPND CAR SCR 145 GEN NXT GNRJ SEQ FRAG ALYS
    0449UCAR SCR SEV INH COND GENOMIC SEQ ALYS PNL 5 GEN
    Molecular pathology and gene-specific CPT codes listedCPTCovered
    81161DMD DUPLICATION/DELETION ANALYSIS
    81221CFTR GENE ANALYSIS KNOWN FAMILIAL VARIANTS
    81222CFTR GENE ANALYSIS DUPLICATION/DELETION VARIANTS
    81223CFTR GENE ANALYSIS FULL GENE SEQUENCE
    81224CFTR GENE ANALYSIS INTRON 8 POLY-T ANALYSIS
    81243FMR1 ANALYSIS EVAL TO DETECT ABNORMAL ALLELES
    81244FMR1 GENE ANALYSIS CHARACTERIZATION OF ALLELES
    81257HBA1/HBA2 ANALYSIS FOR COMMON DELETIONS/VARIANT
    81258HBA1/HBA2 GENE ANALYSIS KNOWN FAMILIAL VARIANT
    81259HBA1/HBA2 GENE ANALYSIS FULL GENE SEQUENCE
    1–10 of 23
    1/3
    Listed molecular pathology and HCPCS codesmixed
    81412ASHKENAZI JEWISH ASSOC DSRDRS GEN SEQ ANAL 9 GEN
    81443GENETIC TESTING FOR SEVERE INHERITED CONDITIONS
    81479UNLISTED MOLELCULAR PATHOLOGY PROCEDURE
    S3845Gene test alpha-thalassemia
    CFTR variant minimum
    Minimum CFTR variant setACMG recommends testing a minimum of 100 CFTR variants when CFTR carrier testing is pursued
    When requiredApply when CFTR carrier testing (sequencing/deletion/duplication or targeted panels) is performed as part of carrier screening
    Source guidanceBased on ACMG 2023 position statement updating CFTR carrier screening variant set to n=100
    Expanded carrier panel gene count
    Expanded panel size (example)Example expanded carrier screening panel described as 145 genes (CPT-PLA 0400U)

    Authorization, Documentation, and Ordering Guidance

    Prior Authorization

    Obtain prior authorization for carrier screening panels (exceptions noted)

    Carrier screening tests described in this policy require prior authorization. Providers must submit prior authorization requests for the carrier screening panels and listed molecular/genetic procedure codes identified in the policy; note that some individual CPTs are called out as covered without preauthorization per policy notes (for example, CPT 81220 and CPT 81329).

    • Submit prior authorization for expanded and basic carrier screening panels and for the molecular/genetic CPT/CPT-PLA/HCPCS codes listed in the policy tables.
    • CPT 81220 (CFTR) and CPT 81329 (SMN1) are noted in the policy as covered benefits that do not require preauthorization per the policy notes; verify coverage notes when submitting.
    • When billing proprietary panel PLA codes (e.g., 0218U, 0236U, 0400U, 0449U) include the authorization for that specific code.
    Denial Risk

    SMN1 sequencing/deletion‑duplication and related tests may be denied if criteria unmet

    Clinical Background and Rationale

    Carrier screening is intended to identify individuals at risk of having offspring with autosomal recessive or X-linked single-gene disorders. Professional guidance supports offering carrier screening in the preconception or prenatal setting; accordingly, this policy conditions coverage on the member considering pregnancy or being currently pregnant, includes requirements for panel composition (for example inclusion of CFTR and SMN1), and requires preauthorization for the reproductive carrier screening tests described.

    Key Definitions

    Carrier screening
    DefinitionTesting to identify individuals at risk of having offspring with inherited recessive or X-linked single-gene disorders by detecting carrier status
    PurposePerformed before or during pregnancy to inform reproductive risk and counseling
    Counseling recommendationPre-test and post-test genetic counseling is strongly advised to support informed decision-making
    Expanded carrier screening panel
    DefinitionMulti-gene panels that include a broad set of genes; medically necessary in pregnancy/preconception only if panel includes CFTR and SMN1
    Authorization noteExpanded panels require preauthorization and may be billed with Fragile X (81243) and SMA (81329) per CPT guidance when performed separately
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyReproductive Testing: Carrier Screening (Requires Preauthorization)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewNov 1, 2026
    Next Review DateAug 11, 2026
    Key ActionObtain prior authorization and submit required clinical documentation (history, office notes, genetic counseling report, and panel gene lists) when requesting carrier screening tests.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCPT / HCPCS / Molecular CodesAuthorization, Documentation, and Ordering GuidanceClinical Background and RationaleKey Definitions
    DMD family testing: For at-risk female relatives of affected males or known heterozygous females, molecular testing (sequencing and/or deletion/duplication analysis) is appropriate; if familial DMD pathogenic variant is unknown and affected male unavailable, perform both CNV analysis and sequencing (~99% sensitivity).

    GeneReviews and EMQN guidance

    CPT/PLA code0400U referenced for 145-gene expanded carrier panel
    Use contextApplied to expanded carrier screening panels when requesting authorization under the listed CPT-PLA
    Minimum genes - Ashkenazi panel
    Ashkenazi panel minimum genesAshkenazi Jewish associated disorders panel must include sequencing of at least 9 genes (CPT 81412)
    Example gene listExamples include ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, SMPD1
    Testing contextOffered to individuals of Ashkenazi Jewish descent who are pregnant or considering pregnancy
    Minimum genes - Severe inherited conditions panel
    Severe inherited conditions panel minimum>= 15 genes required for genomic sequence analysis panel for severe inherited conditions (examples listed)
    CPT referencePolicy references CPT genomic sequence analysis panels with minimum 15 genes (e.g., CPT 81443 descriptions)
    Examples includedExamples of genes in this category include ACADM, ARSA, ASPA, ATP7B, BCKDHA, BLM, CFTR, HBB, HEXA, etc.

    Tests labeled investigational in the policy (for example, SMN1 sequencing/deletion/duplication analysis or SMN2 analysis when criteria are not met) may be denied if the member does not meet the specified medical necessity criteria.

    • Confirm SMA testing meets the policy criteria (member or partner considering pregnancy or partner known carrier) before submitting sequencing/deletion/duplication requests.
    • If criteria are not met, anticipate denial as investigational.
    Prior Authorization

    Submit prior authorization using the listed genetic/molecular codes

    Prior authorization is required for carrier screening tests and the molecular/genetic procedure codes listed in the policy tables; providers should submit the authorization request with supporting clinical records and the specific CPT/CPT‑PLA/HCPCS code to be billed.

    • Include the exact CPT or CPT‑PLA code (for example 0218U, 0236U, 0400U, 0449U) on the authorization request.
    • Attach supporting documentation demonstrating the member meets the medical necessity criteria for the specific test requested.
    Prior Authorization

    Preauthorization required for listed molecular pathology and HCPCS codes

    Preauthorization is required for reproductive carrier screening tests and for the molecular pathology CPT codes and HCPCS identified in the policy (examples include 81412, 81443, 81479, and HCPCS S3845).

    • When requesting authorization, reference the policy-listed molecular pathology CPT codes (e.g., 81412, 81443) or HCPCS (S3845) that correspond to the test.
    • Ensure the selected code matches the panel definition and panel size requirements in the policy.
    Step Therapy

    No step therapy required

    No step therapy requirements are specified in this policy for carrier screening.

    Step Therapy

    Order Ashkenazi panel for the Ashkenazi partner first; test partner only if positive

    For Ashkenazi Jewish panel testing, if only one partner is of Ashkenazi Jewish ancestry, testing that partner first is medically necessary; the other partner should only be tested if the Ashkenazi partner’s result is positive.

    • Order the Ashkenazi Jewish panel for the partner of Ashkenazi ancestry first.
    • Only order testing of the other reproductive partner if the Ashkenazi partner is identified as a carrier.
    Note
    Note
    Documentation Required

    Document pre‑ and post‑test genetic counseling

    Providers should ensure pre‑test and post‑test genetic counseling is performed and documented; counseling should include informed decision‑making, discussion of potential secondary/incidental findings, and a plan for return of results.

    • Document that pre‑test counseling addressed the option to opt out of secondary findings and established a plan for returning results.
    • Include genetic counseling report in the authorization and medical records.
    Documentation Required

    Provide clinical documentation supporting pregnancy status and qualifying family or partner history

    Clinical documentation submitted with authorization requests must support the member’s status (considering pregnancy or currently pregnant) and any qualifying family history or partner carrier status required by the specific test criteria.

    • Include documentation that the member is considering pregnancy or is currently pregnant when required by the criteria.
    • Provide records of a close relative with a known pathogenic or likely pathogenic variant when that is a criterion for the requested test.
    • If testing because of partner carrier status, include the partner’s test results showing carrier status.
    Documentation Required

    Attach History & Physical, office notes, and genetic counseling report to the authorization

    Include recommended medical records to support authorization: History & Physical report, office visit notes, and the genetic counseling report.

    • Attach History and Physical, relevant office notes, and the genetic counseling report to the prior authorization request.
    • Lack of these records may prevent support of prior authorization or claim adjudication.
    Documentation Required

    Submit gene lists, methodology, and exact test code with authorization

    Providers must submit documentation that the test meets the panel definitions (for example, gene lists and test methodology) and specify the CPT/CPT‑PLA/HCPCS code that corresponds to the panel being requested.

    • Provide the laboratory’s gene list or panel composition to demonstrate the panel meets the policy minimum gene counts (eg, Ashkenazi panel ≥9 genes; severe inherited conditions panel ≥15 genes).
    • State the laboratory methodology and the exact billing code (e.g., 0400U, 0449U, 81412, 81443) on the authorization request.
    Denial Risk

    Avoid billing expanded/basic panels for non‑pregnancy indications (risk of denial)

    Expanded and basic carrier screening panels billed for indications other than members considering pregnancy or currently pregnant (except where partner‑carrier context applies) are considered investigational and may be denied.

    • Do not request authorization for expanded or basic panels for indications outside preconception/prenatal unless documentation shows a policy‑allowed partner‑carrier context.
    • If an expanded or basic panel is submitted for a non‑covered indication, expect denial for investigational use.
    Note
    Denial Risk

    Do not bill Fragile X testing outside specified criteria (denial risk)

    Fragile X (FMR1 CGG repeat analysis) billed outside the specified criteria (premature ovarian insufficiency, or pregnancy/considering pregnancy with qualifying family history) is considered investigational and may be denied.

    • Only request Fragile X testing when the member meets the listed criteria (premature ovarian insufficiency or qualifying family history) or when pregnant/considering pregnancy with qualifying family history.
    • If billing FMR1 testing with a carrier panel (e.g., 81443), ensure the member meets the Fragile X criteria even when billed with the panel.
    Denial Risk

    Hemoglobinopathy testing billed outside pregnancy/qualifying history may be denied

    Hemoglobinopathy targeted or sequencing testing performed outside the indications (not pregnant/considering pregnancy or lacking qualifying family history) is investigational and may be denied.

    • Ensure hemoglobinopathy testing requests include documentation of pregnancy intent/status or qualifying family history.
    • Fetal hemoglobin testing via circulating fetal DNA is investigational and excluded from coverage.
    Denial Risk

    Insufficient documentation may result in denied authorization or claim

    Failure to provide the recommended medical records (History & Physical, office notes, genetic counseling report) or required documentation may lead to inability to support prior authorization or claim adjudication.

    • Include all recommended records with the authorization request to avoid processing delays or denials.
    • If requested documentation is missing, the payer may deny the request for insufficient information.
    Prior Authorization

    Verify and obtain preauthorization per policy header

    Preauthorization is required for reproductive carrier screening as indicated in the policy header; do not send charges for these panels without obtaining authorization when required.

    • Verify the policy header and notes for specific CPT exceptions before ordering.
    • Obtain authorization prior to testing to ensure coverage where required.
    Example codeCPT-PLA 0400U cited for a 145-gene expanded carrier panel
    Basic carrier screening panel
    DefinitionPanels limited to key genes (CFTR, SMN1/2, FMR1, HBB/HBA1/HBA2) with no more than 14 genes; medically necessary when member is considering pregnancy or currently pregnant and panel includes CFTR and SMN1
    Gene limitNot more than 14 genes per basic panel definition
    UsageConsidered investigational for indications other than preconception or pregnancy
    Close relatives
    Definition of close relativesFirst-, second-, and third-degree relatives on the same side of the family
    First-degree examplesParents, siblings, children
    Second- and third-degree examplesSecond-degree: grandparents, aunts/uncles, nieces/nephews, grandchildren, half-siblings; Third-degree: great grandparents, great aunts/uncles, great grandchildren, first cousins
    Fragile X premutation carrier testing
    Indications for Fragile X premutation testingOffer Fragile X premutation carrier testing to women with personal or family history of ovarian failure or elevated FSH before age 40 without known cause
    Test referenceFMR1 CGG repeat analysis is the method referenced for Fragile X carrier testing
    Coverage limitationFragile X testing billed outside specified criteria is considered investigational
    Hemoglobinopathy testing
    RecommendationUniversal hemoglobinopathy testing is recommended at the initial prenatal visit for individuals considering pregnancy or currently pregnant
    MethodsTesting may be hemoglobin electrophoresis or molecular testing/expanded carrier screening
    ContextUsed to identify carriers of alpha- and beta-hemoglobinopathies to inform reproductive counseling
    Ashkenazi Jewish carrier screening
    Panel recommendationTargeted Ashkenazi Jewish carrier panel testing recommended for individuals of Ashkenazi Jewish descent (includes CF, Canavan, familial dysautonomia, Tay-Sachs)
    Partner testing orderIf only one partner is Ashkenazi Jewish, test that partner first; test the other partner only if the first is a carrier
    Offer contextOffer to individuals who are pregnant or considering pregnancy
    DMD carrier testing
    When to perform DMD carrier testingPerform targeted molecular testing of at-risk female relatives when a familial pathogenic DMD variant is known
    When familial variant unknownIf familial DMD variant is unknown and affected male unavailable, offer both CNV analysis and sequencing (~99% sensitivity) per EMQN guidance
    Testing goalsIdentify heterozygous females for management (eg, cardiac surveillance) and reproductive counseling
    Ashkenazi Jewish associated disorders panel
    Ashkenazi-associated disorders panel requirementGenomic sequence analysis panel must include sequencing of at least 9 genes (eg, ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, SMPD1)
    CPT referenceCPT 81412 describes Ashkenazi Jewish associated disorders panel with >=9 genes
    Intended populationIntended for individuals of Ashkenazi Jewish descent who are pregnant or considering pregnancy
    Genetic testing for severe inherited conditions panel
    Severe inherited conditions panel requirementGenomic sequence analysis panel must include sequencing of at least 15 genes for genetic testing of severe inherited conditions
    Examples of genesExamples listed include ACADM, ARSA, ASPA, ATP7B, BCKDHA, BLM, CFTR, HBB, HEXA, IKBKAP, MCOLN1, PAH, etc.
    CPT referenceReferenced in CPT description for panels of severe inherited conditions (eg, CPT 81443/related descriptors)